1970 Buick Skylark Custom Convertible 69,000 Documented Miles on 2040-cars

Auto blog

Buick to kill Verano as early as 2017

The Buick Verano's days are allegedly numbered. Citing unnamed sources, Automotive News is reporting that Buick will kill its Delta-platform-based sedan. The company offered the typical "no comment." According to AN, Buick is expecting 70 percent of its sales to come from the Encore, Envision, and Enclave once the Envision goes on sale. And it doesn't take a professor of economics to recognize that when half the vehicles you build account for just 30 percent of the sales, it's time to trim. But the case for killing the Verano is a weird one, because the problem isn't a lack of demand. Struggling sales might be the reason to kill a car, but the Verano is – and has consistently been – Buick's second best-selling sedan. It's beaten the slightly larger, more expensive Regal by at least 12,000 units in each of the last four years. Hell, in 2013, Buick sold 45,000 Veranos to fewer than 19,000 Regals. So why not kill the Regal? Well, the Verano's raison d'etre is irrelevant today. Buick launched its smallest sedan at a time when premium compact four-doors weren't a thing and gas prices were high enough that consumers were still hesitant to tie themselves to a CUV's fuel bill. And while it was roughly the same size as the Chevrolet Cruze that it shared GM's Delta platform with, it had enough unique equipment to stand apart and warrant its price premium. Today, fuel prices are cheap and consumers are flocking to crossovers while Buick is stuck sharing the premium compact pie with much more prestigious names ( Mercedes-Benz and Audi). And because it's sharing showroom space with the super-popular Encore, even the Verano's affordable pricing has become a liability. Today, a lightly equipped Verano is the same price as a base Encore, and they offer broadly similar features (rear-view cameras, a seven-inch touchscreen with Intellilink, Bluetooth, etc.). And if the Encore is too small, there's probably a GMC Terrain sitting in the same showroom, offering more utility and equal equipment to the Verano for a similar price. As one dealer told AN, "For not much more money, customers can get an SUV." Killing the Verano might risk 30,000 to 40,000 sales, but it's a move that proves Buick has tremendous confidence in its CUV lineup – clearly the company thinks the Encore can do the job of luring customers into showrooms. AN's sources claim the Verano will survive through 2017, so we'll be waiting a few years to find out if that faith is misplaced. Related Video:

Opel Cascada close to getting green light for US

For a company with a long tradition of grand touring convertibles, it's almost unseemly that General Motors doesn't offer a properly relaxed four-seat convertible in North America. There's the Chevrolet Camaro, of course, but it's not big on rear-seat space and it doesn't offer that sort of serene demeanor that many open-air buyers crave. We're thinking of something more refined and, dare we say, elegant. Something a bit closer to the Opel Cascada.
The General's front-wheel drive convertible went on sale in Europe this year, and while it seemed like a natural fit for its Buick brand in America, it's never been sold here. That may be about to change, however. Back in June, CEO Dan Akerson hinted he'd like to see the Cascada available in the US, and now there's word from Edmunds that importation "could happen soon." That's according to an unnamed insider at the company.
It's almost unseemly that GM doesn't offer a relaxed four-seat convertible.

Submit your questions for Autoblog Podcast #310 LIVE!

We record Autoblog Podcast #310 tonight, and you can drop us your questions and comments regarding the rest of the week's news via our Q&A module below. Subscribe to the Autoblog Podcast in iTunes if you haven't already done so, and if you want to take it all in live, tune in to our UStream (audio only) channel at 10:00 PM Eastern tonight.
Discussion Topics for Autoblog Podcast Episode #310
Buick GN and GNX will return